Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

Biological Psychiatry

Volumn 47, Issue 9, 2000, Pages 818-829

  Wong, Erik H F ^a   Sonders, Mark S ^c   Amara, Susan G ^c   Tinholt, Paula M ^a   Piercey, Montford F P ^a   Hoffmann, William P ^a   Hyslop, Deborah K ^a   Franklin, Stanley ^a   Porsolt, Roger D ^b   Bonsignori, Alberto ^a   Carfagna, Nicola ^a   McArthur, Robert A ^a  

^a PFIZER INC   (United States)

^b (RDP)   (France)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antidepressants; Monoamine transporters; Norepinephrine; Preclinical pharmacology; Reboxetine; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG TOLERANCE; DRUG USE; HUMAN; PRIORITY JOURNAL;

EID: 17544404431     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00291-7     Document Type: Article

References (55)

1. Aghajanian G.K., Foote W.E., Sheard M.H. Action of psychotogenic drugs on single midbrain raphe neurons. J Pharmacol Exp Ther. 137:1970;178-187.
2. Archer J.A., Cole J.O., Clin J.-N., Feiger J.P., Ferris R.M., Fibinger H.C., et al. Bupropion A review of its mechanism of antidepressant activity . J Clin Psychiatry. 56:1995;393-401.
3. Aston-Jones G., Chiang C., Alexinsky T. Discharge of noradrenergic locus coerulus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res. 88:1991;501-520.
4. Berzewdski H., Van Moffaert M., Gagiano C.A. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive disorder. Eur Neuropsychopharmacol. 7:(suppl 1):1997;S37-S47.
5. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 15:1994;220-226.
6. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
7. Buckley N.A., McManus P.R. Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 18:1998;369-381.
8. Bunney B.S., Walters J.R., Roth R.H., Aghajanian G.K. Dopaminergic neurons Effect of antipsychotic drugs and amphetamine on single cell activity . J Pharmacol Exp Ther. 185:1973;560-571.
9. Cedarbaum J.M., Aghajanian G.K. Noradrenergic neurons of the locus coeruleus Inhibition by epinephrine and activation by the α-antagonist piperoxan . Brain Res. 112:1976;413-419.
10. 50) of an enzymatic reaction. Biochem Pharmacol. 22:1973;3099-3108.
11. Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 113:1967;1237-1264.
12. Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors Focus on newer generation compounds . Psychopharmacology (Berl). 114:1994;559-565.
13. Davidson J.R.T. Sexual dysfunction and antidepressants. Depression. 2:1995;233-240.
14. de Boer T.H., Nefkens F., van Helvoirt A., van Delft A.M. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 277:1996;852-860.
15. Dostert P., Benedetti M.S., Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropyschopharmacol. 7:(suppl 1):1997;S23-S35.
16. Dubini A., Bosc M., Polin V. Do noradrenaline and serotonin differentially affect social motivation and behavior? Eur Neuropsychopharmacol. 7:(suppl 1):1997;S49-S55.
17. Finkel M.S., Laghrissi T.F., Pollock B.G., Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull. 32:1996;653-658.
18. Foote S.L., Aston-Jones G.S. Pharmacology and physiology of central noradrenergic systems. Bloom F.E., Kupfer D.J. Psychopharmacology, the Fourth Generation of Progress. 1995;335-345 Raven, New York.
19. Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol. 17:(2):1997;2S-18S.
20. Grimsley S.R., Jann M.W. Paroxetine, sertraline, and fluvoxamine New selective serotonin reuptake inhibitors . Clin Pharmacol. 11:1992;930-957.
21. Harkin A., Kelly J.P., McNamara M., Connor T.J., Dredge K., Redmond A., et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol. 364:1999;123-132.
22. Hemrick-Luecke S.K., Snoddy H.D., Fuller R.W. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 55:1994;479-483.
23. Hindmarch I. The effects of antidepressants on psychomotor performance with particular reference to reboxetine. Eur Neuropsychopharmacol. 7:(suppl 1):1997;S17-S21.
24. Irwin S. Comprehensive observational assessment Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse . Psychopharmacologia. 13:1968;222-257.
25. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression An update . Pharmacol Ther. 74:1997;299-316.
26. Koe B.K., Weissman A., Welch W.M., Browne R.G. Sertraline 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther. 226:1983;686-700.
27. Leonard B.E. The role of noradrenaline in depression A review . J Psychopharmacol. 11:(suppl 4):1997;S39-S47.
28. Melloni M., Carnici G., Della Torre A., Bonsignori A., Buonamici M., Pozzi O., et al. Potential antidepressant agents. α-aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur J Med Chem. 3:1984;235-242.
29. Mendels J. The acute and long-term treatment of major depression. Int Clin Psychopharmacol. 7:1992;21-29.
30. Montgomery S.A. Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol. 7:(suppl 1):1997;S3-S9.
31. Mucci M. Reboxetine A review of antidepressant tolerability . J Psychopharmacol. 11:(suppl 4):1997;S33-S39.
32. Muth E.A., Moyer J.A., Haskin J.T., Andree T.H., Husbands G.E.M. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 23:1991;191-199.
33. Nguyen T.T., Amara S.G. N-Linked oligosaccharides are required for cell surface expression of the norepinephrine transporter but do not influence substrate or inhibitor recognition. J Neurochem. 67:1996;645-666.
34. Olivier B., Bosch L., van Hest A., van der Heyden J., Mos J., van der Poel G., et al. Preclinical evidence on the psychotropic profile of fluvoxamine. Pharmacopsychiatry. 26:(suppl 1):1993;2-9.
35. Pacholczyk T., Blakely R.D., Amara S.G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 350:1991;350-354.
36. Paul I.A., Nowak G., Layer R.T., Popik P., Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther. 269:1994;95-102.
37. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sydney.
38. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats A new model sensitive to antidepressant treatments . Eur J Pharmacol. 47:1978;379-391.
39. Priest R.G., Baldwin D.S., Dullock T., Kibel D., Smeyatsky N., Steinert J. Recent advances in antidepressant drugs. S Afr Med J. 6:1992;1-4.
40. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry. 52:1991;4-10.
41. Richelson E., Nelson A. Antagonism by antidepressants of neurotransmitter receptor of normal human brain in vitro. J Pharmacol Exp Ther. 230:1984;94-102.
42. Richelson E., Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes Most antidepressants selectively block norepinephrine uptake . Eur J Pharmacol. 104:1984;277-286.
43. Rickels K., Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry. 51:(suppl B):1990;9-12.
44. Riva M., Brunello N., Rovescalli A.C., Galimberti R., Carfagna N., Carminati P., et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system Behavioural and biochemical studies . J Drug Dev. 1:1989;243-253.
45. Schildkraut J.J. The catecholamine hypothesis of affective disorders A review of supporting evidence . Am J Psychiatry. 122:1965;509-522.
46. Scuvee-Moreau J.J., Dresse A.E. Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat. Eur J Pharmacol. 57:1979;219-225.
47. Seiden L.S., O'Donnell J.M. Effects of antidepressant drugs on DRL behavior. Seiden L.S., Balster R. Behavioral Pharmacology The Current Status . 1985;323-338 Alan R Liss, New York.
48. Steru L., Chermat R., Thierry B., Mico J.-A., Lenegre A., Steru M., et al. The automated tail suspension test A computerized device which differentiates psychotropic drugs . Prog Neuropsychopharmacol Biol Psychiatry. 11:1987;659-671.
49. Svensson T.H., Usdin T. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants α-Receptor mediation . Science. 202:1978;1089-1091.
50. Taylor D.P., Carter R.B., Eison A.S., Mullins U.L., Smith H.L., Torrente J.R., et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 56:1995;3-11.
51. Thase M.E. Depression, sleep, and antidepressants. J Clin Psychiatry. 59:(suppl 4):1998;55-65.
52. Thomas D.R., Nelson D.R., Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl). 93:1987;193-200.
53. van Hest A., van Drimmelen M., Olivier B. Flesinoxan shows antidepressant activity in a DRL 72-s screen. Psychopharmacology (Berl). 107:1992;474-479.
54. Vaugeois J.M., Passera G., Zuccaro F., Costentin J. Individual differences in response to imipramine in the mouse tail suspension test. Psychopharmacology (Berl). 134:1997;387-391.
55. Versiani M., Mehilane L., Gaszner P., Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry. 60:1999;400-406.